S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   1303
 
                        2025-2026 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              January 9, 2025
                                ___________
 
 Introduced  by  M.  of  A.  ROSENTHAL, SIMON, GALLAGHER, GLICK, SHIMSKY,
   REYES, CRUZ, LEVENBERG, WALKER, TAYLOR, RAGA,  DE LOS SANTOS  --  read
   once and referred to the Committee on Health
 
 AN  ACT to amend the public health law, in relation to the creation of a
   research program to determine the risks posed from potential toxins in
   menstrual products; and providing for the repeal  of  such  provisions
   upon expiration thereof
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Short title. This act shall be known and may  be  cited  as
 "the menstrual product safety and research act".
   § 2. The public health law is amended by adding a new section 267-c to
 read as follows:
   §  267-C.  MENSTRUAL  PRODUCT  SAFETY AND RESEARCH. 1. FOR PURPOSES OF
 THIS SECTION, THE TERM "MENSTRUAL PRODUCTS" MEANS TAMPONS, PADS, LINERS,
 CUPS, SPONGES, DOUCHES, WIPES, SPRAYS,  AND  SIMILAR  PRODUCTS  USED  IN
 CONJUNCTION   WITH   RESPECT  TO  MENSTRUATION  OR  OTHER  GENITAL-TRACT
 SECRETIONS.
   2. THE COMMISSIONER SHALL  PROVIDE  FOR  THE  CONDUCT  OR  SUPPORT  OF
 RESEARCH BY THE DEPARTMENT TO DETERMINE THE EXTENT TO WHICH THE PRESENCE
 OF  DIOXINS, SYNTHETIC FIBERS, CHLORINE, AND OTHER COMPONENTS (INCLUDING
 CONTAMINANTS AND SUBSTANCES USED AS  FRAGRANCES,  COLORANTS,  DYES,  AND
 PRESERVATIVES) IN MENSTRUAL PRODUCTS:
   (A) POSES ANY RISKS TO THE HEALTH OF INDIVIDUALS WHO USE THE PRODUCTS,
 INCLUDING RISKS RELATING TO CERVICAL CANCER, ENDOMETRIOSIS, INFERTILITY,
 OVARIAN  CANCER,  BREAST  CANCER,  IMMUNE  SYSTEM  DEFICIENCIES,  PELVIC
 INFLAMMATORY DISEASE, TOXIC SHOCK  SYNDROME,  AND  BACTERIAL  AND  YEAST
 INFECTIONS; AND
   (B) POSES ANY RISKS TO THE HEALTH OF BIOLOGICAL CHILDREN BORN TO INDI-
 VIDUALS  WHO  USED  SUCH  PRODUCTS  DURING  OR  BEFORE  THE  PREGNANCIES
 INVOLVED, INCLUDING RISKS RELATING TO FETAL AND CHILDHOOD DEVELOPMENT.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD03818-01-5
              

 A. 1303                             2
 
   3. RESEARCH UNDER  SUBDIVISION  TWO  OF  THIS  SECTION  SHALL  INCLUDE
 RESEARCH  TO  CONFIRM  THE  DATA  ON MENSTRUAL PRODUCTS SUBMITTED TO THE
 UNITED STATES FOOD AND DRUG  ADMINISTRATION  BY  MANUFACTURERS  OF  SUCH
 PRODUCTS.
   4.  SUCH RESEARCH PROJECTS SHALL BE COMPLETED WITHIN FOUR YEARS OF THE
 EFFECTIVE DATE OF THIS SECTION.
   5. WITHIN ONE YEAR OF THE COMPLETION OF  SUCH  RESEARCH,  ANY  CONCLU-
 SIONS,  RECOMMENDATIONS  AND PROPOSALS FOR IMPLEMENTING SUCH RECOMMENDA-
 TIONS SHALL BE TRANSMITTED TO THE GOVERNOR, THE TEMPORARY  PRESIDENT  OF
 THE  SENATE, THE SPEAKER OF THE ASSEMBLY, THE CHAIR OF THE SENATE HEALTH
 COMMITTEE, AND THE CHAIR OF THE ASSEMBLY  HEALTH  COMMITTEE,  AND  SHALL
 ALSO BE MADE AVAILABLE TO THE PUBLIC.
   §  3.  This  act shall take effect on the ninetieth day after it shall
 have become a law and shall expire and be  deemed  repealed  five  years
 after such date.